Physician profile
Prashant Natteru
NPI 1790205078
$1,260.04
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $76.58 · 2021: $107 · 2022: $130 · 2023: $733 · 2024: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $525 · Food and Beverage: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $525.00 |
| Food and Beverage | $312.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $525.00 | 2023 | |
| Jazz Pharmaceuticals INC. | $173.39 | 2022-2023 | Epidiolex |
| Abbott Laboratories | $150.97 | 2023 | Infinity |
| Genzyme Corporation | $121.61 | 2019-2021 | |
| Abbvie INC. | $104.17 | 2024 | |
| Acorda Therapeutics, INC | $54.85 | 2019-2020 | |
| Ucb, INC. | $39.86 | 2021 | |
| Genentech USA, INC. | $28.09 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $19.46 | 2020 | |
| Lilly USA, LLC | $16.59 | 2020 | |
| Sk Life Science, INC. | $14.39 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Natteru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.